Director/PDMR Shareholding

DXS INTERNATIONAL PLC

Notification of Director / PDMR Dealing

The Board of DXS International plc (the “Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems has received notification and notified the market that on 4 December 2023 Mr Bob Sutcliffe purchased a total of 400,000 Ordinary Shares in the Company at a price of 2.5p per share on behalf of himself and others.

One of the other persons acquiring beneficial ownership of Ordinary Shares as a result of Mr Sutcliffe’s purchase is David Immelman, the DXS Chief Executive, who has acquired a beneficial interest in 40,000 Ordinary Shares. Following this transaction Mr Immelman, and persons connected to him, have an interest in DXS Ordinary Shares of 6,563,829 Ordinary Shares representing 10.25% of the issued share capital of the Company.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	David Immelman
2	Reason for the notification
a)	Position/status	Chief Executive
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	DXS INTERNATIONAL PLC
b)	LEI	2138001R1KEUWTXEVJ44
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.33p each

	Identification code	ISIN GB00B2Q6HZ92

b)	Nature of the transaction	Issue of new shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			2.5p	40,000

d)	Aggregated information

	- Aggregated volume

	- Price

e)	Date of the transaction	4 December 2023
f)	Place of the transaction	Aquis Stock Exchange

The Directors of DXS International plc accept responsibility for this announcement.

Enquiries:

David Immelman (Chief Executive)DXS International plc	01252 719800david@dxs-systems.com
Wrecclesham HouseWrecclesham RoadFarnhamSurreyGU10 4PS
www.dxs-systems.co.uk

Corporate Advisor
David PapworthCity & Merchant	0207 101 7676

Corporate Broker
Hybridan LLPClaire Louise Noyce	020 3764 2341

Note to Editors:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.

DXS (AQSE:DXSP)
過去株価チャート
から 10 2024 まで 11 2024